Selecting between the Jeep Compass and Tata Safari would depend on certain factors such as your budget, features required, space on offer, preference of the segment, etc. Tata Safari has the ability ...

Compass remains a buy as it outpaces industry growth and leverages the Anywhere Real Estate acquisition. Click here to read an analysis of COMP stock now.

U.S. antitrust enforcers should consider blocking a bid by Compass, the nation’s largest residential real estate broker, to acquire rival Anywhere Real Estate, amid a housing shortage, two Democratic ...

New research reveals how the invasive fall armyworm uses a combination of the Earth's magnetic field and visual cues to navigate during night-time migration.

Nocturnal insects may use both Earth's magnetic field and visual cues to guide their migratory flight behaviors, according to recent findings. The research, published in eLife, presents compelling ...

Compass, Inc. (NYSE:COMP) is one of the 12 Best Stocks Under $10 to Invest In Right Now. On February 9, UBS raised its price target on Compass, Inc. (NYSE:COMP) from $12 to $17 and maintained its Buy ...

Q4 2025 Earnings Call February 26, 2026 5:00 PM ESTCompany ParticipantsSoham Bhonsle - Head of Investor RelationsRobert Reffkin ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A psychedelic medicine for hard-to-treat depression ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the ...